Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAS: Intermittent Relugolix + ARPI in mHSPC
NCT07216248Phase 2Recruiting
- Sponsor
- University of Utah
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by University of Utah. Started Oct 2025; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07216248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216248.